`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`INC., AMARIN
`PHARMA,
`AMARIN
`IRELAND
`PHARMACEUTICALS
`LIMITED, MOCHIDA PHARMACEUTICAL
`CO.,LTD.
`
`Plaintiffs;
`
`Civil Action No. 20-1630-RGA-JLH
`
`V.
`
`HIKMA PHARMACEUTICALS USA INC.,
`HIKMA PHARMACEUTICALS PLC, AND
`HEALTH NET, LLC,
`
`Defendants.
`
`ORDER
`
`For the reasons stated in the accompanying Memorandum Opinion, Hikma's motion to
`
`dismiss the First Amended Complaint (D.I. 19) is GRANTED. Hikma's motion to dismiss the
`
`original complaint (D.I. 11) is DISMISSED AS MOOT. Health Net's motion to dismiss the
`
`First Amended Complaint (D.I. 30) is DENIED. The first amended complaint (D.I. 17) as to the
`
`Hikma Defendants is DISMISSED without prejudice. 1
`
`IT IS SO ORDERED this 4th day of January 2022.
`
`1 Plaintiffs requested leave to amend if the first amended complaint was dismissed. (DJ. 22 at 20). Plaintiffs gave
`no indication as to what more they could plead, but if they have something more, they may file a motion in
`compliance with the Local Rules seeking leave to amend.
`
`Page I of 1
`
`